PP 1 (SKU: A8215): Selective Src Family Tyrosine Kinase Inhibitor in Cancer and Immunology Research

Executive Summary: PP 1 (SKU: A8215) is a chemically defined inhibitor of Src-family tyrosine kinases with nanomolar potency for Lck (IC₅₀ = 5 nM) and Fyn (IC₅₀ = 6 nM) (APExBIO, product page). It demonstrates high selectivity, sparing Syk kinase while efficiently targeting Lyn and RET oncoproteins (IC₅₀ = 80 nM for RET) (Hanke et al., PMID:9261151). PP 1 blocks critical signal transduction in T cells, modulating IL-2 expression and proliferation (Hanke et al., PMID:9261151). Its role in inhibiting metastatic and proliferative phenotypes in cancer models underscores its translational utility (Cancer Letters 2025). APExBIO supplies PP 1 as a solid, water-insoluble compound, optimized for DMSO or ethanol-based research workflows (APExBIO).

Biological Rationale

Src family kinases (SFKs) are a group of non-receptor protein tyrosine kinases including Src, Lck, Fyn, and Lyn. These enzymes orchestrate signal transduction regulating cell division, motility, adhesion, and survival (Cancer Letters 2025). In oncogenesis, aberrant SFK activation drives tumor initiation, progression, and metastasis. In immune cells, SFKs modulate T cell receptor signaling, activation, and cytokine production. Selective inhibition of SFKs enables researchers to dissect their distinct contributions to cancer cell proliferation, metastatic dissemination, and immune synapse formation (Mechanistic Precision in Oncology). PP 1 (SKU: A8215) was developed to provide nanomolar precision in modulating these critical pathways (APExBIO).

Mechanism of Action of PP 1 (SKU: A8215) Src family tyrosine kinase inhibitor

PP 1 is a small-molecule inhibitor with the chemical name 1-tert-butyl-3-(4-methylphenyl)pyrazolo[3,4-d]pyrimidin-4-amine (MW 281.36, C₁₆H₁₉N₅). It binds competitively to the ATP-binding pocket of SFKs, preventing kinase phosphorylation activity. PP 1 exhibits high selectivity for Lck and Fyn, with IC₅₀ values of 5 nM and 6 nM, respectively (APExBIO). It also inhibits Lyn at nanomolar concentrations but does not affect Syk kinase at comparable doses (Hanke et al., PMID:9261151). PP 1 suppresses RET-derived oncoproteins (IC₅₀ = 80 nM), leading to morphological reversion and loss of proliferative autonomy in cancer cells (Cancer Letters 2025).

Evidence & Benchmarks

• PP 1 inhibits Lck with an IC₅₀ of 5 nM in cell-free kinase assays (Hanke et al., PMID:9261151).
• Fyn kinase activity is blocked at an IC₅₀ of 6 nM under identical conditions (APExBIO).
• PP 1 does not inhibit Syk kinase at concentrations up to 1 μM, confirming selectivity (Hanke et al., PMID:9261151).
• In RET/PTC3-transformed cells, PP 1 (≤80 nM) induces loss of proliferative autonomy and reverts oncogenic morphology (Cancer Letters 2025).
• In T cells, PP 1 suppresses tyrosine phosphorylation and proliferation, reducing IL-2 gene expression (Hanke et al., PMID:9261151).

For a comparative overview of PP 1’s nanomolar selectivity in translational oncology, see Mechanistic Precision in Oncology. This article extends previous guides by providing quantitative benchmarks and cross-model evidence, building on protocol-focused resources such as PP 1 Src Family Tyrosine Kinase Inhibitor: Precision Tool.

Applications, Limits & Misconceptions

PP 1 (SKU: A8215) is widely used in cancer cell line studies, immune cell activation assays, and mechanistic dissection of Src kinase signaling pathways. It is essential for experiments requiring selective ablation of Lck, Fyn, and Lyn without off-target interference with Syk or unrelated kinases. Its ability to inhibit RET oncogene signaling supports its use in models of RET-driven cancers.

Common Pitfalls or Misconceptions

• Not a pan-tyrosine kinase inhibitor: PP 1 is selective for Src-family kinases and does not inhibit all tyrosine kinases (e.g., Syk).
• Not clinically approved: There are no clinical trials or approved therapeutic indications for PP 1; it is for research use only (APExBIO).
• Limited water solubility: PP 1 is insoluble in aqueous buffers and must be prepared in ethanol or DMSO (≥7.03 mg/mL in DMSO; ≥20.6 mg/mL in ethanol with ultrasonic assistance).
• Short-term storage for solutions: Working solutions are recommended for immediate or short-term use; long-term storage may result in degradation.
• Not suitable for in vivo therapeutic studies: Lack of pharmacokinetic and safety data limits its direct translation to animal or human therapy.

Workflow Integration & Parameters

PP 1 is supplied as a solid compound requiring dissolution in DMSO or ethanol. For cell-based assays, prepare fresh stock solutions at concentrations appropriate for target inhibition (typically nanomolar to low micromolar). Store the solid desiccated at 4°C. Avoid repeated freeze-thaw cycles for solutions. For optimal selectivity, titrate concentrations and include appropriate kinase activity controls. For protocols and troubleshooting strategies, see Advanced Experimental Guide, which this article updates with more recent benchmarking data.

Conclusion & Outlook

PP 1 (SKU: A8215) remains a gold-standard tool for selectively inhibiting Src family tyrosine kinases in cancer and immunology research. Its nanomolar potency and selectivity profile enable precise interrogation of oncogenic and immune signaling networks. Recent studies underscore the importance of SFKs in metastatic cancer biology and immune modulation (Cancer Letters 2025). As the field advances, integrating PP 1 with emerging molecular and cellular assays will further elucidate the roles of Src kinases, supporting both mechanistic insight and translational innovation. For product specifications and detailed usage recommendations, refer to the official PP 1 (SKU: A8215) Src family tyrosine kinase inhibitor page.